We found that combination of let-7b repletion with paclitaxel or gemcitabine diminished both MEK/ERK and PI3K/AKT signaling in KRAS mutant tumor cells, leading to substantial increase in apoptosis. This evidence concerns the gene MAP2K7 and neoplasm.